Markush claims in China - what can be arbitrarily deleted during invalidation?
Since 2010, the China Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that discusses post filing data in China patents.
This case (Beijing Winsunny Harmony Science & Technology Co., Ltd. v. Daiichi Sankyo Co., Ltd) describes an invalidation request of Daiichi Sankyo’s Chinese invention patent 97126347.7 related to processes of preparing pharmaceutical compositions for treating or preventing hypertension. The patent covered the marketed hypertension drug Olmesartan medoxomil.
During the invalidation, the patentee made select amendments to multiple Markush groups, deleting particular individual components from several different R groups of a molecule. The issue at hand is whether these amendments are allowable during an invalidation proceeding, which typically has very strict rules regarding amendments.
Courts Differ on Markush Claims in China
In short, it boils down to how the courts interpret a Markush claim. Does it refers to a general technical solution or parallel embodiments of several technical solutions? If it is one general solution, should you really be able to pick and carve away at its scope? Does doing so create a new scope that has a different technical effect than the original invention? If so, is that allowable?
The Patent Re-examination Board (PRB) and the Beijing High People’s Court (BHPC) disagreed on how to interpret Markush claims in China. The PRB felt that arbitrary amendments should not be allowed because a Markush claim is directed towards a general technical solution. Arbitrarily deleting elements during invalidation would thus create new scopes of protection that could have different technical solutions.
The BHPC thought that Markush groups represented alternate parallel technical solutions, and thus deleting one or more options just narrowed the scope of the claim. The Supreme People’s Court (SPC) ruled that the amendments were allowable. Additionally, the SPC indicated that such types of amendments may be allowed during invalidation as long as the amendments did not generate a scope that possessed a new function or technical effect.
Markush Claims in China Drafting Tips
Applicants should be aware that amendments which carve out a new scope with improved technical effect (as compared to the original scope) may not be allowable. During an invalidation proceeding, it will be difficult to amend claims to a narrower scope with improved technical results to overcome inventive step. Instead, at the time of drafting, applicants should draft several dependent claims directed towards alternate scopes with varying qualities of efficacy, including very narrow claims covering the best, most efficacious compounds. It is risky to rely on being able to carve out scope from broader claims during an invalidation challenge.
A side note on inventive step . . .
Interestingly, this case also briefly discussed inventive step. The petitioners argued that the patent lacked inventive step because a specific embodiment in the patent had equivalent technical effect as a prior art compound. The PRB disagreed and emphasized that inventiveness is actually a three-step determination, and it is inappropriate to directly apply just the “unexpected technical effect” test to see if claims are inventive or not.
Sources: Lexology, Sanyou IP Group
China Releases Details on Patent Term Extension, Deferred Examination and More in the Latest Draft Implementation Rules of the New Chinese Patent Law
2020年12月11日
The China National Intellectual Property Administration (CNIPA) is moving forward at breakneck speeds aiming to get all the necessary pieces in place for the June 1, 2021 date when the new 4th Amendment of the Patent Law will come into effect. Most recently, this means a flurry of drafts coming out from CNIPA, including, but […]
阅读更多 >
China’s Newest Examination Guidelines: Novelty and Inventive Step for Compounds (Part II)
2021年4月29日
This is Part II of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]
阅读更多 >
A Detailed Dive into China’s New Patent Term Extension Provisions
2020年12月11日
This article is a part of a larger article that highlights the newest draft implementation rules of the new Chinese Patent Law. This particular article takes a detailed dive into the patent term extension/adjustment provisions. One of the biggest and most exciting provisions in the newly amended patent law is patent term extension for delay […]
阅读更多 >
Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical
2023年12月12日
Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]
阅读更多 >
我们的过去活动
Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho Named Patent Stars by ManagingIP
2025年6月13日
Eagle IP Ranked Among Top Tier Firms in IAM Patent 1000
2025年6月12日
Jennifer Che from Eagle IP to Attend BIO 2025 in Boston!
2025年6月11日
Insights from HKSTP Market Discovery - BIO Connect
2025年5月28日
HKMHDIA Medical Fair Forum
2025年5月27日
Celebrating Innovation at the Asia Summit for Global Health
